Aro Biotherapeutics

Aro Biotherapeutics has pioneered the development of Centyrins, a scaffold protein technology platform that offers superior stability with high specificity and affinity for antigens of interest, for use in targeted genetic medicines. By conjugating Centyrins to therapeutic oligonucleotides, Aro aims to revolutionize tissue- and cell-specific drug targeting to expand the abilities of genetic medicines to treat an array of diseases beyond those in the liver or in the central nervous system.